PackTalk is a blog for the Healthcare Packaging Industry

Eli Lilly Starts Human Study of Potential COVID-19 Antibody Test


Published on June 4, 2020

Companies and research institutions around the world are racing to find a viable treatment for COVID-19, which has already caused ~370,000 deaths worldwide and continues to rise. Eli Lilly recently announced their progress, and are moving into the human study portion of their antibody treatment. They have developed this treatment from a blood sample that was taken from one of the first patients in the United States to have recovered from the lung illness caused by COVID-19. 

Eli Lilly is anticipating results to their study by end of June. Read more about the treatment here.


Comments (0)

Related Articles

Cold Chain Packaging: Packaging Engineers Wanted

July 30, 2021

COVID-19 has put a public spotlight on the economic global demands and challenges related to cold chain drug supply and delivery. And while the growth trends in the world of cold chain packaging are not new, the focus is certainly heightened, leading...

Learn More

How Particulate Control Can Save or Destroy Your Next Launch

July 30, 2021

In the midst of a pandemic raging across the world, pharmaceutical companies are more and more alerted to the dangers and risks of drug product contamination. The recent FDA-ordered destruction of 60 million vaccine doses is one very prominent example. One...

Learn More

The Next Decade of Medical Packaging Belongs to China  – Part 3

July 30, 2021

The final part of our three-part series examines China’s role in the global supply chain for medical devices and packaging. A strong central government and experience managing pandemics led the country to a rapid rebound ahead of other economies.

Part 3:...

Learn More

Stay Informed

To stay up to date on innovative technology and products, as well as industry trends, subscribe to Oliver’s PackTalk blog below.